Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3559676 Target Snapshot

GP41 · SINGLE PROTEIN · Human immunodeficiency virus 1

25Compounds
9Assays
2Approved Drugs
40.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

GP41 shows late clinical disease relevance led by AIDS. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q76270. Start with AIDS, then reuse UniProt Q76270 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with AIDS, then reuse UniProt Q76270 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
AIDS

GP41 shows late clinical disease relevance led by AIDS. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with AIDS because it currently carries late clinical support. Linked drugs include ALBUVIRTIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats GP41 as ChEMBL target CHEMBL3559676, mapped to UniProt Q76270. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
GP41
SINGLE PROTEIN · Human immunodeficiency virus 1
As of 2026-09-14
ChEMBL target ID
CHEMBL3559676
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q76270
Env polyprotein
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether GP41 is the right protein anchor across sources, using UniProt Q76270 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why AIDS is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEnv polyprotein
UniProt AccessionQ76270
Component TypeProtein
Sequence Length124 aa

Env polyprotein

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as GP41, mapped to UniProt Q76270. ChEMBL maps the protein component as Env polyprotein. Sequence length is 124 aa.

Mapped IDQ76270
Review nameGP41
OrganismHuman immunodeficiency virus 1
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

GP41 shows late clinical disease relevance led by AIDS. 3 more disease programs remain visible in the same review block.

Late clinical Phase III
AIDS
1 linked drug · 1 direct · 1 efficacy
Linked drugALBUVIRTIDE
Late clinical Phase III
HIV infection
1 linked drug · 1 direct · 1 efficacy
Linked drugALBUVIRTIDE
Late clinical Phase III
HIV-1 infection
1 linked drug · 1 direct · 1 efficacy
Linked drugALBUVIRTIDE
Late clinical Phase III
viral disease
1 linked drug · 1 direct · 1 efficacy
Linked drugALBUVIRTIDE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with AIDS because it currently carries late clinical support. Linked drugs include ALBUVIRTIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseAIDS
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
Assay Mix

Activity Type Distribution

IC508.0
EC5029.0
KD3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2380932 8.89 EC50 1.3 Preclinical
CHEMBL3341857 8.48 EC50 3.31 Preclinical
CHEMBL3341856 8.47 EC50 3.35 Preclinical
CHEMBL3341854 8.4 EC50 3.94 Preclinical
CHEMBL3341855 8.1 EC50 7.94 Preclinical
CHEMBL525076 8.0 EC50 10.1 Approved
CHEMBL3341847 7.82 EC50 15.1 Preclinical
CHEMBL3341852 7.71 EC50 19.6 Preclinical
CHEMBL3341849 7.54 EC50 28.6 Preclinical
CHEMBL3341853 7.36 EC50 44.2 Preclinical
Distribution

pChEMBL Value Distribution

8
5.0
2
5.5
4
6.0
7
6.5
3
7.0
5
7.5
5
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

ENFUVIRTIDE
CHEMBL525076
Approved 2003
Assay Landscape

Assay Landscape

9
Total Assays
30
Tested Compounds
1
Assay Types
Binding — 9 assays, 30 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 5 11 5.6
cell-based format 4 19 7.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine